| Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer (NCT03912857) | Sun Yat-sen University | 2018-12-01 |
| Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer (NCT03307603) | Case Comprehensive Cancer Center | 2018-12-01 |
| FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients (NCT03721653) | Gruppo Oncologico del Nord-Ovest | 2018-11-30 |
| Sym004 Versus Futuximab or Modotuximab in Patients With mCRC (NCT03549338) | Symphogen A/S | 2018-11-29 |
| SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer (NCT03645876) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-08 |
| Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer (NCT03712943) | H. Lee Moffitt Cancer Center and Research Institute | 2018-10-23 |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer (NCT03668431) | Massachusetts General Hospital | 2018-10-15 |
| Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer (NCT03182894) | James J Lee | 2018-09-30 |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options (NCT03602885) | Dana-Farber Cancer Institute | 2018-09-01 |
| Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer (NCT04561336) | University of Campania Luigi Vanvitelli | 2018-08-10 |
| Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (NCT03376659) | Georgetown University | 2018-08-08 |
| Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC). (NCT03564938) | Bayer | 2018-07-30 |
| Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy (NCT03908788) | Institut du Cancer de Montpellier - Val d'Aurelle | 2018-07-26 |
| A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (NCT03547999) | Patrick Boland | 2018-06-26 |
| Trifluridin/tipirACil in MeTastatIc Colorectal Cancer (NCT03665506) | Servier | 2018-06-25 |
| EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer (NCT03542799) | Shenzhen Second People's Hospital | 2018-05-22 |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status (NCT03457896) | NSABP Foundation Inc | 2018-05-18 |
| Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (NCT03340558) | Niharika Mettu | 2018-05-01 |
| A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer (NCT04247984) | Chinese Academy of Medical Sciences | 2018-05-01 |
| FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (NCT03584711) | Federation Francophone de Cancerologie Digestive | 2018-04-26 |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (NCT03186326) | Federation Francophone de Cancerologie Digestive | 2018-04-24 |
| Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer (NCT03435107) | Asan Medical Center | 2018-04-12 |
| A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy (NCT03454620) | Green Cross Corporation | 2018-04-02 |
| Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC (NCT03274804) | University Hospital Heidelberg | 2018-04-01 |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases (NCT03256344) | Amgen | 2018-03-19 |
| Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial (NCT03426371) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2018-03-18 |
| Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (NCT03374254) | Merck Sharp & Dohme LLC | 2018-02-16 |
| Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC (NCT03405272) | Sinocelltech Ltd. | 2018-02-12 |
| Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer (NCT03485027) | Fudan University | 2018-01-24 |
| Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer (NCT03391934) | Cinnagen | 2018-01-20 |
| Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma (NCT05316818) | Kasr El Aini Hospital | 2018-01-16 |
| CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (NCT03206151) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2017-12-12 |
| AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer (NCT01741038) | Mirror Biologics, Inc. | 2017-12-01 |
| Mix Vaccine for Metastatic Colorectal Cancer (NCT03357276) | Fuda Cancer Hospital, Guangzhou | 2017-11-30 |
| A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer (NCT03356158) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2017-11-15 |
| Immunophenotyping of Metastases From Colorectal Cancer (NCT03604926) | Istituto Oncologico Veneto IRCCS | 2017-10-05 |
| PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (NCT03176264) | Novartis Pharmaceuticals | 2017-09-25 |
| First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (NCT03231722) | Gruppo Oncologico del Nord-Ovest | 2017-09-13 |
| Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer (NCT03263429) | Vanderbilt-Ingram Cancer Center | 2017-08-23 |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (NCT03117972) | Centre Hospitalier Universitaire de Besancon | 2017-08-04 |
| Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC (NCT03222089) | Fujian Cancer Hospital | 2017-07-20 |
| Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (NCT03174405) | AIO-Studien-gGmbH | 2017-07-17 |
| Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer (NCT04393116) | Cankado GmbH | 2017-07-11 |
| To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC. (NCT02249650) | Taiwan Sunpan Biotechnology Development Co., Ltd. | 2017-07-10 |
| Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) (NCT03146338) | Weprom | 2017-07-04 |
| The CHOICE Registry (NCT03148093) | Taiho Oncology, Inc. | 2017-06-30 |
| Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer (NCT03081494) | Novartis Pharmaceuticals | 2017-06-09 |
| Circulating Tumor Cells in mCRC for Liver Resection (NCT03295591) | The University of Hong Kong | 2017-06-01 |
| Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer (NCT02981524) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-05-26 |
| Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer (NCT03150706) | Asan Medical Center | 2017-05-22 |
| Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies (NCT03291379) | Boston Scientific Corporation | 2017-05-17 |
| Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients (NCT03210064) | Hui ting Xu，MD | 2017-05-04 |
| Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer (NCT03132025) | Yanqiao Zhang | 2017-04-30 |
| A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer (NCT03122509) | Memorial Sloan Kettering Cancer Center | 2017-04-24 |
| Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (NCT03168139) | TME Pharma AG | 2017-04-18 |
| The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer (NCT03220984) | Gangnam Severance Hospital | 2017-03-16 |
| Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies (NCT03274882) | Institut de Recherches Internationales Servier | 2017-03-03 |
| Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) (NCT03043950) | iOMEDICO AG | 2017-01-25 |
| A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer (NCT03031691) | OncoMed Pharmaceuticals, Inc. | 2017-01-01 |
| Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer (NCT03017807) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2016-12-30 |
| Donafenib for Previously Treated Metastatic Colorectal Cancer (NCT02870582) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2016-12-28 |
| A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer (NCT03035253) | OncoMed Pharmaceuticals, Inc. | 2016-12-01 |
| High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer (NCT03008499) | Fuda Cancer Hospital, Guangzhou | 2016-12-01 |
| Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (NCT02980510) | UNICANCER | 2016-12-01 |
| Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients (NCT02965417) | Symphogen A/S | 2016-12-01 |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (NCT04034459) | Ludwig-Maximilians - University of Munich | 2016-11-25 |
| Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (NCT02970916) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2016-11-01 |
| A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). (NCT03306394) | Institut de Recherches Internationales Servier | 2016-10-18 |
| Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer (NCT03288987) | AryoGen Pharmed Co. | 2016-10-04 |
| Special Combination of BBI608 and Pembrolizumab (NCT02851004) | Takayuki Yoshino | 2016-10-01 |
| HepaSphere™ Microspheres Prospective Registry (NCT04866290) | Merit Medical Systems, Inc. | 2016-09-22 |
| Resection Observatory (NCT05178745) | Sanofi | 2016-09-07 |
| Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer (NCT02906059) | NYU Langone Health | 2016-09-01 |
| Phase II Study of Perindopril and Regorafenib in mCRC (NCT02651415) | British Columbia Cancer Agency | 2016-08-01 |
| Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer (NCT02872779) | University Hospital, Rouen | 2016-07-18 |
| Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (NCT02835924) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2016-07-01 |
| Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer (NCT02848443) | Institut de Recherches Internationales Servier | 2016-05-01 |
| A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (NCT02743221) | Institut de Recherches Internationales Servier | 2016-04-29 |
| The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment (NCT03130634) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2016-04-01 |
| Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy (NCT02597075) | Swiss Cancer Institute | 2016-03-17 |
| Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (NCT02568046) | Symphogen A/S | 2016-03-15 |
| A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab (NCT02673710) | Hoffmann-La Roche | 2016-03-14 |
| A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer (NCT02615574) | Pawel Kalinski | 2016-03-01 |
| ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer (NCT02587247) | Nantes University Hospital | 2016-03-01 |
| Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer (NCT02827565) | Institut de Cancérologie de Lorraine | 2016-02-03 |
| Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer (NCT02654639) | Georgetown University | 2016-02-01 |
| Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib (NCT02699073) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2016-02-01 |
| Local Ablative Strategies After Endovascular Radioembolization (NCT02611661) | Washington University School of Medicine | 2016-01-19 |
| Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas (NCT02973672) | Surgimab | 2016-01-01 |
| Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (NCT02624726) | Hellenic Oncology Research Group | 2016-01-01 |
| ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (NCT02624895) | Amgen | 2015-12-30 |
| Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects (NCT02310464) | OBI Pharma, Inc | 2015-12-22 |
| Pemetrexed and Erlotinib for Metastatic Colorectal Cancer (NCT02723578) | Yonsei University | 2015-12-01 |
| A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer (NCT02641873) | Sumitomo Pharma Co., Ltd. | 2015-12-01 |
| Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer (NCT02623621) | Azienda Ospedaliero, Universitaria Pisana | 2015-11-01 |
| Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer (NCT03286738) | Joong Bae Ahn | 2015-11-01 |
| LifePearl-Iri Pharmacokinetic Study (NCT02547480) | Terumo Europe N.V. | 2015-11-01 |
| Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials (NCT03350412) | Fondazione del Piemonte per l'Oncologia | 2015-10-01 |
| Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer (NCT02575378) | Ruijin Hospital | 2015-09-01 |
| Abscopal Effect for Metastatic Colorectal Cancer (NCT02535988) | Zhejiang Provincial People's Hospital | 2015-09-01 |